An FDA advisory committee narrowly endorsed expanding access to several compounded, unapproved peptides, delivering a procedural win for proponents of the substances and for Health Secretary Robert F. Kennedy Jr. The vote concerned whether additional peptides should be added to the Section 503A Bulk Drug Substances List, a non-binding recommendation that the FDA can accept or reject. The committee’s stance comes despite objections from FDA staff and scientists who highlighted limited evidence for benefit and unresolved safety questions. The decision is expected to influence whether compounding pharmacies can manufacture the peptides more broadly while the FDA retains ultimate authority. In parallel coverage, the outcome underscored how quickly well-organized “wellness” demand can collide with evidence-based standards, with supporters arguing patient access and opponents warning an end-run around clinical development and manufacturing controls. For biotech stakeholders, the episode is less about the peptides themselves and more about precedent: how regulators handle active ingredients that have not met FDA approval benchmarks, and how those choices can reshape the competitive and compliance landscape for drug development.